Swedbank AB Buys 8,761 Shares of DexCom, Inc. (NASDAQ:DXCM)

Swedbank AB lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 4.1% during the 4th quarter, Holdings Channel reports. The firm owned 222,625 shares of the medical device company’s stock after buying an additional 8,761 shares during the quarter. Swedbank AB’s holdings in DexCom were worth $17,314,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in DXCM. Hantz Financial Services Inc. raised its position in DexCom by 12,699.4% in the 4th quarter. Hantz Financial Services Inc. now owns 116,091 shares of the medical device company’s stock valued at $9,028,000 after purchasing an additional 115,184 shares during the last quarter. Nvest Financial LLC bought a new position in shares of DexCom in the fourth quarter valued at about $200,000. Smith Group Asset Management LLC acquired a new position in DexCom during the 4th quarter worth about $3,266,000. Mount Yale Investment Advisors LLC bought a new stake in DexCom during the 4th quarter worth about $713,000. Finally, Union Bancaire Privee UBP SA acquired a new stake in DexCom in the 4th quarter valued at about $225,000. 97.75% of the stock is owned by institutional investors.

DexCom Stock Performance

Shares of DexCom stock opened at $86.83 on Friday. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $33.92 billion, a PE ratio of 51.99, a PEG ratio of 2.22 and a beta of 1.12. The stock’s fifty day simple moving average is $80.49 and its 200 day simple moving average is $76.67.

Analyst Ratings Changes

DXCM has been the topic of several research analyst reports. Raymond James decreased their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research note on Friday, October 25th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Wells Fargo & Company boosted their target price on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Citigroup raised their price target on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average target price of $99.29.

Insider Transactions at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,342 shares of company stock valued at $3,628,069 over the last 90 days. 0.30% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.